Eisai Inc makes a US promotion

Shaji Procida becomes vp and cfo

Eisai Inc, the US pharmaceutical subsidiary of Eisai Co of Japan, has promoted Shaji Procida to the position of vice president and chief financial officer.

Previously, Procida held the position of vice president of finance. In her new role, she will have responsibility for all of Eisai's financial operations in the US. In addition, she will continue to serve as a member of the company's executive committee.

You may also like

Regulatory

Alzheimer's drug lecanemab deemed unsuitable for the UK NHS by health regulator

The drug will not be available on the NHS owing to significant and potentially life-threatening side effects, as well as the cost of the medicine and its limited efficacy
Research & Development

Eisai, BMS and H3 Biomedicine announce research collaboration

Bristol-Myers Squibb, Eisai and its US-based precision medicine research and development subsidiary H3 Biomedicine, have announced a multiyear research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer
Ingredients

Eisai enters into joint research agreement with the Broad Institute, Colorado State University and University of Chicago

On the development of a potential new treatment for tuberculosis
Regulatory

Patent battle for Aloxi in the US

Helsinn Healthcare and Eisai fall foul of reversed court decision regarding Teva Pharmaceuticals and Aloxi patent for the US market
Finance

Eisai realigns US operations

Company will reduce workforce by 25% to create a more efficient and focused organisation
Manufacturing

Eisai to expand global packaging facility in UK

Japanese firm will invest £8 million at its production plant in Hatfield, Hertfordshire to support the planned launch of several new products
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now